ERBB2 and gastric cancer: According to a recent case study on patients with HER2-positive advanced gastric cancer and brain metastases, the combined treatment of pyrotinib, trastuzumab, and chemotherapy produced a PFS of 20 months, which is significantly longer than the median survival time of 2.9–6.2 months for most patients with advanced gastric cancer (Wang et al., 2022).